Opening soon. Stay in the loop

goodmorrowJoin the opening list

Epitalon, explained.

Epithalon. Research, safety questions, and treatment context.

Updated Clinical review pending · Educational draft

The form

Preparation matters

The routine

No personal schedule is set by this guide.

The evidence

See the evidence and source notes below.

Research, approval and availability are separate questions.

Legal status
Backed by FDA advisers, awaiting final rule

FDA advisers voted 7 to 4 on July 24, 2026 to allow compounding, after reviewing it for insomnia.

At Goodmorrow
Waitlist open

What it is

Epitalon is a synthetic version of a peptide extract from the pineal gland, the part of the brain that manages melatonin and sleep timing.

What the evidence shows

Most of the research comes from one group of Russian scientists, and the longevity claims rest heavily on cell studies of telomeres. The FDA reviewed it for insomnia.

How Goodmorrow handles it

We'll consider it for sleep once it's lawful. On longevity, the honest answer is that nobody has shown it extends life in people.

Stacks that include it

Follow updates about Epitalon

Join the update list. This does not reserve a treatment or mean that future availability is assured.

What are you interested in?

We'll only use this to contact you about appointments, by phone, text or email. No health details needed here. See our privacy policy.

Questions people ask

Does epitalon lengthen telomeres?

It did in cell studies. Whether that happens in people, and whether it would matter if it did, hasn't been shown.

Sources

  1. Secondary sourceFDA advisory panel narrowly rejects compounding of one peptide, backs two others STAT, July 24, 2026
  2. FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
  3. Secondary sourceBulk-list bound? PCAC backs majority of peptides in two-day public meeting McDermott Will & Schulte, July 28, 2026

Good days ahead.

Join the opening list for appointment updates.

Join the opening list